Go to the list of all blogs
Rick Johnson's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
Purple Biotech (PPBT): Narrowing In on the CAPTN-3 Platform

Purple Biotech (PPBT): Narrowing In on the CAPTN-3 Platform

Key Takeaways

  • The single most important near-term catalyst is advancing IM1240, the lead tri-specific antibody from the CAPTN-3 platform, toward a planned Phase 1 clinical trial, with recent toxicology and manufacturing milestones de-risking the path.
  • Purple Biotech has narrowed its strategy sharply around CAPTN-3, a masked tri-specific antibody platform that engages both T cells and natural killer (NK) cells while using "capping" technology to confine immune activation to the tumor microenvironment.
  • Legacy clinical assets CM24 and NT219 were impaired in late 2025, and their future development now depends on securing a partner or strategic investment, making partnership execution a pivotal swing factor.
  • The company ended 2025 with roughly $9.5 million in cash, which management expects to fund operations into 2027, but additional capital raises or partnering are likely to influence dilution and sentiment.
  • Analyst coverage remains thin; H.C. Wainwright has maintained a Buy rating while revising its price target lower, reflecting both the platform's promise and rising financing and execution uncertainty.
  • As a clinical-stage biotech, PPBT is highly sensitive to the funding environment, regulatory timelines, and broader risk appetite in the biotechnology sector.

Strategic Focus and Competitive Landscape

Purple Biotech Ltd. is a clinical-stage immunotherapy company headquartered in Rehovot, Israel, focused on next-generation antibody therapies for solid-tumor cancers. Its strategic center of gravity is now the CAPTN-3 platform, which produces "masked" tri-specific antibodies designed to bind a tumor-associated antigen while simultaneously engaging T cells and NK cells. The capping design is intended to keep immune activation localized to the tumor, potentially widening the therapeutic window relative to conventional T-cell engagers.

The lead candidate, IM1240, targets the 5T4 antigen, while the second candidate, IM1305, targets TROP2. Both are aimed at solid tumors associated with advanced disease and poor outcomes. Positive preclinical data presented at the ESMO Immuno-Oncology Congress 2025, along with toxicology results showing improved tolerability at doses up to 300-fold higher than a non-capped comparator, support the platform's differentiating thesis. Management has also reported commercially viable manufacturing yields, a meaningful step for a complex multi-valent antibody. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Structurally, the company has concentrated its limited resources on one platform and de-emphasized two clinical-stage assets, CM24 and NT219, whose continued development is contingent on partnering or external funding. This focus simplifies the investment case but also concentrates risk: the near-term valuation narrative now rests largely on the execution of a single preclinical-to-Phase 1 program.

Major Catalysts on the Horizon

The clearest growth catalyst on the horizon is the planned initiation of a Phase 1 clinical trial for IM1240. Successfully filing an investigational new drug application and dosing the first patient would mark a transition from preclinical promise to clinical validation, a threshold that typically drives re-rating in early-stage biotech. Additional preclinical data disclosures on IM1240 and IM1305 through 2026 could further shape investor sentiment.

Partnership activity is a second pivotal catalyst. Because CM24 (a CEACAM1-blocking antibody) and NT219 (a dual IRS1/2 and STAT3 inhibitor) can only advance with outside capital or a collaborator, any licensing deal or strategic investment would both validate the broader pipeline and reduce financing pressure.

Capital allocation is equally important. With roughly $9.5 million in cash at year-end 2025 and a stated runway into 2027, future equity raises could dilute existing holders but also extend the company's ability to reach clinical milestones.

On analyst sentiment, coverage is limited. H.C. Wainwright has maintained a Buy rating while lowering its 12-month price target in stages, from $34 to $30 and subsequently to $17, a signal of tempered optimism. Consensus ratings across data providers range from "Hold" to "Moderate Buy," and the thin coverage means individual revisions can carry outsized influence on the stock forecast.

Industry Context and Broader Influences

Purple Biotech operates at the intersection of two active oncology themes: T-cell engagers and masked (conditionally activated) antibodies. Industry attention to cytokine release syndrome and other immune-related toxicities has increased demand for technologies that promise potency without systemic side effects, a tailwind aligned with CAPTN-3's design.

Macro conditions matter indirectly through the financing channel. Clinical-stage companies without product revenue depend on equity markets, and higher-for-longer interest rates or a risk-off environment can raise the cost of capital and pressure valuations across the biotech sector. Inflation trends influence R&D and manufacturing costs, while the regulatory climate, particularly the U.S. Food and Drug Administration's stance on novel antibody formats, will shape development timelines. Geopolitical considerations tied to the company's Israeli headquarters and operations can also periodically affect execution and investor sentiment.

2026 Outlook and Longer-Term Considerations

Looking into 2026 and beyond, the defining question is whether CAPTN-3 can translate compelling preclinical data into clinical proof of concept. A successful early readout would position the platform as a differentiated player in the crowded but high-value solid-tumor immunotherapy market, while any safety or manufacturing setback could sharply reset expectations given the concentrated pipeline.

Longer-term themes include the evolution of masked-antibody science, where competitors are also pursuing conditionally activated approaches; cost-structure discipline, as a lean organization must stretch limited cash across multi-year clinical development; and capital-allocation priorities, which will hinge on whether management funds IM1240 organically, via partnerships, or through additional equity raises. Regulatory developments governing tri-specific antibody formats and the trajectory of oncology partnership activity will also be important signposts.

Consensus expectations remain modest and thinly covered, and external price targets should be read strictly as analyst projections rather than guarantees. For investors evaluating the future outlook, the key variables are clinical execution, partnering success, and the durability of the company's funding runway, each of which will shape the trajectory of the PPBT stock forecast over the medium term.

Exploring AI Tools for Biotech Analysis

In my own workflow, I find Tickeron's AI Trend Prediction Engine useful for getting a data-driven perspective on near-term price direction. This AI-powered tool helps flag potential bullish, bearish, or sideways trends over the coming weeks or months and can complement fundamental research on names like PPBT by highlighting timing signals alongside clinical and financial analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PPBT

PPBT in upward trend: price rose above 50-day moving average on November 11, 2026

PPBT moved above its 50-day moving average on November 11, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 37 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on PPBT as a result. In 65 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for PPBT just turned positive on October 30, 2026. Looking at past instances where PPBT's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.

The 10-day moving average for PPBT crossed bullishly above the 50-day moving average on November 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Following a +4.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where PPBT advanced for three days, in 169 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

PPBT broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PPBT entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. PPBT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.172) is normal, around the industry mean (3.592). P/E Ratio (-0.027) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PPBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of pharmaceutical drug discovery and development services

Industry Biotechnology

Industry
Pharmaceuticals Major
Address
4 Oppenheimer Street
Phone
+972 39333121
Employees
10
Web
https://www.purple-biotech.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.